ArticleBlood cancer journal2023

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.

Yi Miao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.